Single Ascending Dose Study in Participants With LCA10

Inclusion Criteria: * Male or female * At least 3 years of age at screening with CEP290-related retinal degeneration caused by a homozygous or compound heterozygous mutation involving c.2991+1655A\>G in IVS26 of the CEP290 gene. * Visual Acuity: * Sentinel participant will have severe vision loss with a logMAR BCVA of ≥1.6 to 3.9 (20/800 or worse to LP) in the study eye * Non-sentinel participants must have BCVA between 1.0 - 3.0 logMAR in the study eye Exclusion Criteria: * Other known disease-causing mutations * Achieves a passing score for the mobility course at the most difficult level * In either eye, active systemic or ocular/intraocular infection or inflammation * In either eye, history of steroid-responsive intraocular pressure with increases \> 25 mm Hg following corticosteroid exposure * Any vaccination/immunization in the last 28 days before screening * Inability or unwillingness to take oral prednisone * Prior gene therapy or oligonucleotide treatment